Compare Eli Lilly And Co (LLY) vs ThredUp Inc (TDUP) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

TDUP trades at $6.57, down 0.45% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth of 15% year-over-year to $81.7 million, though it missed EPS expectations. Analyst consensus is bullish with a $6.90 price target, and recent news highlights AI integration and a new peer-to-peer marketplace launch.

The outlook is cautiously optimistic due to strong revenue growth and improving gross margins, but persistent net losses and negative ROE pose risks. Upside potential exists if profitability improves, yet investors face execution and competitive threats in the resale market.